GlaxoSmithKline plc
GlaxoSmithKline plc (GSK.SW) Stock Competitors & Peer Comparison
See (GSK.SW) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GSK.SW | CHF 19.98 | N/A | 101.6B | 18.76 | CHF 1.07 | N/A |
| LLY.SW | CHF 720.00 | -7.69% | 554.8B | 39.60 | CHF 18.18 | +0.68% |
| RO.SW | CHF 332.00 | +0.73% | 264.3B | 20.69 | CHF 16.05 | +3.08% |
| ROG.SW | CHF 322.30 | +0.50% | 256.6B | 20.11 | CHF 16.03 | +3.04% |
| NOVN.SW | CHF 123.20 | +0.24% | 235.1B | 21.54 | CHF 5.72 | +1.95% |
| BAYN.SW | CHF 36.97 | +0.00% | 36.3B | -11.13 | -CHF 3.32 | +0.28% |
| COPN.SW | CHF 86.90 | +0.58% | 1.4B | -413.81 | -CHF 0.21 | +2.21% |
Stock Comparison
GSK.SW vs LLY.SW Comparison April 2026
GSK.SW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GSK.SW stands at 101.6B. In comparison, LLY.SW has a market cap of 554.8B. Regarding current trading prices, GSK.SW is priced at CHF 19.98, while LLY.SW trades at CHF 720.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GSK.SW currently has a P/E ratio of 18.76, whereas LLY.SW's P/E ratio is 39.60. In terms of profitability, GSK.SW's ROE is +0.38%, compared to LLY.SW's ROE of +0.98%. Regarding short-term risk, Volatility data is not available for a full comparison. GSK.SW has daily volatility of N/A and LLY.SW has daily volatility of 0.00.Check LLY.SW's competition here